PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9

Zhang,Xing-Guang; Lu,Xiao-Feng; Jiao,Xiu-Ming; Chen,Bin; Wu,Jin-Xiao

doi:10.3892/etm.2012.729

PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9

Authors:
- Xing-Guang Zhang
- Xiao-Feng Lu
- Xiu-Ming Jiao
- Bin Chen
- Jin-Xiao Wu
View Affiliations

Affiliations: Department of Endocrinology, The Military General Hospital of Beijing PLA, Beijing 100700, P.R. China
Published online on: September 28, 2012 https://doi.org/10.3892/etm.2012.729
Pages: 1005-1009

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to observe the regulatory action of the polo-like kinase 1 (PLK1) gene in the invasion of anaplastic thyroid carcinoma cells and investigate its mechanisms. The expression of the PLK1 protein in 36 patients with anaplastic thyroid carcinoma was detected by immunohistochemical staining. siRNA against PLK1 was designed, synthesized and transfected into ARO cells. The effects of PLK1 siRNA on cell invasion were detected by a soft agar colony formation assay and a Transwell chamber assay. The corresponding protein was detected using western blot analysis. The expression of PLK1 in anaplastic thyroid carcinoma samples (67.5±10.6%) was significantly higher compared to that in cancer-adjacent samples (0.65%±0.12%; P<0.01). The expression of PLK1 correlated with clinical stage, lymph node metastasis and prognosis of anaplastic thyroid. The number of cell clones was reduced in a dose-dependent manner with increasing levels of siRNA and the number of cells permeating through the filter membrane decreased following transfection with siRNA. The inhibition of PLK1 caused a significant decrease in CD44v6, matrix metalloproteinase (MMP)-2 and MMP-9 (0.36±0.08, 0.12±0.03, 0.25±0.06, respectively) compared to the non-transfected group (1.15±0.18, 1.21±0.20, 1.25±0.21, respectively; P<0.01). In conclusion, the expression of PLK1 was found to be increased in anaplastic thyroid carcinoma and was correlated with clinical stage, lymph node metastasis and prognosis. Additionaly, PLK1 siRNA was found to inhibit the invasion of anaplastic thyroid carcinoma cells. Therefore, CD44v6, MMP-2 and MMP-9 are likely to be involved in the regulation of cell invasion induced by PLK1.

View Figures

View References

1	van de Weerdt BC and Medema RH: Polo-like kinases: a team in control of the division. Cell Cycle. 5:853–864. 2006.PubMed/NCBI
2	Degenhardt Y and Lampkin T: Targeting Polo-like kinase in cancer therapy. Clin Cancer Res. 16:384–389. 2010. View Article : Google Scholar : PubMed/NCBI
3	Liu YZ, Yu L, Gong DD, et al: Construction of PLK1 siRNA and its effects on proliferation and apoptosis of undifferentiated human thyroid cancer cells. Chin J Endocr Surg. 5:76–79. 2011.(In Chinese).
4	Feng YB, Lin DC, Shi ZZ, et al: Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer. 124:578–588. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zhao CL, Gong L, Li WT and Chen L: Overexpression of Plk1 promotes malignant progress in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 136:9–16. 2010. View Article : Google Scholar : PubMed/NCBI
6	Evans RP, Dueck G, Sidhu R, et al: Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma. Leuk Res. 35:1637–1643. 2011. View Article : Google Scholar : PubMed/NCBI
7	Noriyuki T and Hisashi N: Polo-like kinases (Plks) are prognostic markers for gynecologic malignancies. Cur Womens Health Rev. 4:266–269. 2008. View Article : Google Scholar
8	Schmit TL, Zhong WX, Nihal M and Ahmad N: Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle. 8:2697–2702. 2009. View Article : Google Scholar : PubMed/NCBI
9	He ZL, Zheng H, Lin H, et al: Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol. 15:4177–4182. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lan B, Liu BY, Chen XH, et al: Polo like kinase 1 expression and prognostic value in gastric carcinomas. Zhonghua Wei Chang Wai Ke Za Zhi. 10:70–72. 2007.(In Chinese).
11	Zhang Y, Liu Y, Yang YX, et al: The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity. J Exp Clin Cancer Res. 28:130–139. 2009. View Article : Google Scholar : PubMed/NCBI
12	Salvatore G, Nappi TC, Salerno P, et al: A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res. 67:10148–10158. 2009. View Article : Google Scholar : PubMed/NCBI
13	Nappi TC, Salerno P, Zitzelsberger H, et al: Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res. 69:1916–1923. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kojic SL, Strugnell SS and Wiseman SM: Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Rev Anticancer Ther. 11:387–402. 2011. View Article : Google Scholar : PubMed/NCBI
15	Thullberg M and Strömblad S: Anchorage-independent cytokinesis as part of oncogenic transformation? Cell Cycle. 7:984–988. 2008. View Article : Google Scholar : PubMed/NCBI
16	Marshall J: Transwell(®) invasion assays. Methods Mol Biol. 769:97–110. 2011.
17	Duffy MJ, Mc Gowan PM and Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol. 214:283–293. 2008. View Article : Google Scholar : PubMed/NCBI
18	Jung T, Gross W and Zöller M: CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem. 286:15862–15874. 2011. View Article : Google Scholar : PubMed/NCBI
19	Cho Mar K, Eimoto T, Tateyama H, et al: Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology. 48:286–294. 2006.PubMed/NCBI
20	Tan H, Ye K, Wang Z and Tang H: Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma. Jpn J Clin Oncol. 38:528–533. 2008. View Article : Google Scholar : PubMed/NCBI
21	Buergy D, Weber T, Maurer GD, et al: Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer. 125:894–901. 2009. View Article : Google Scholar : PubMed/NCBI
22	Rothhut B, Ghoneim C, Antonicelli F and Soula-Rothhut M: Epidermal growth factor stimulates matrix metalloproteinase-9 expression and invasion in human follicular thyroid carcinoma cells through focal adhesion kinase. Biochimie. 89:613–624. 2007. View Article : Google Scholar